Skip to main content

Table 1 Summary of study participant characteristics

From: Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

Study name Study design 8-AQ duration Dose Adult dose (mg)a Total adult dose (mg) Malaria Country Setting Population Age PQ compared to placebo in G6PD deficient people PQ in G6PD deficient compared to G6PD replete people
Primaquine
 Krudsood [24] Randomized control trial 7 days 30 mg 30 210 Yes Thailand Patients Primary care urban 16–51 years No Yes
 Shekalaghe [22] Randomized control trial Once 0.75 mg/kg 45 45 Yes Tanzania Residents Rural 3–15 years Yes Yes
 Shekalaghe [23] Randomized control trial Once 0.75 mg/kg 45 45 No Tanzania Residents Rural 1–11 years Yes Yes
 Eziefula [27, 33] Randomized control trial Once 0.1, 0.4 or 0.75 mg/kg 6, 24, 45 6, 24, 45 Yes Uganda Residents Unknown 1–10 years Yes Yes
 Kheng [30] Open parallel clinical trial Once 0.75 mg/kg 45 45 No Cambodia Healthcare centres   Adults and children No Yes
 Bancone [29] Cohort study Once 0.25 mg/kg 15 15 No North-Western Myanmar–Thailand border Residents Rural Adults and children No Yes
 Ley [31] Cohort study Once 0.75 mg/kg 45 45 Yes Bangladesh Healthcare Rural Adults and children No Yes
 Mwaiswelo [28] Randomized control trial Once 0.25 mg/kg 15 15 Yes Tanzania Dispensary Town Men and non-pregnant, non-lactating women aged ≥1 year Yes Yes
Tafenoquine
 Rueangweerayut [32] Cohort study Once 100 mg (1.67 mg/kg), 200 mg (3.33 mg/kg), 300 mg (5.00 mg/kg) 100, 200, 300 100, 200, 300 No Thailand Laboratory Research institute 18–45 years  No  Yes
  1. aAdult dose—assuming 60 kg adult